Last reviewed · How we verify
Xenbilox — Competitive Intelligence Brief
phase 2
Other
Small molecule
Live · refreshed every 30 min
Target snapshot
Xenbilox (Xenbilox) — Institut National de la Santé Et de la Recherche Médicale, France.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Xenbilox TARGET | Xenbilox | Institut National de la Santé Et de la Recherche Médicale, France | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
Cite this brief
Drug Landscape (2026). Xenbilox — Competitive Intelligence Brief. https://druglandscape.com/ci/xenbilox. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing